ArticleEBioMedicine2025
Significance of integrated clinical and proteomic characteristics analysis for pathogenesis and management of Crohn's disease with concomitant psoriasis.
Article in EBioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardiovascular risk in inflammatory bowel disease: focus on lipids and visceral adipose tissue.Frontiers in endocrinology · 2026Review
- Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn's disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCertain patients with Crohn's disease (CD) concomitantly develop psoriasis (PS), whilst the typical features and underlying mechanisms remain under investigation. The present study was intended to identify the clinical and proteomic features of CD with concomitant PS (CDPS) in order to enhance future diagnostic and therapeutic strategies for this type of comorbidity.
methodsA retrospective, single-centre study was conducted for patients with CD, CDPS, and idiopathic PS. Student's t-test, Wilcoxon rank-sum test and the Chi-square test were employed to examine the similarities and differences of clinical characteristics of these patients. Intestinal mucosa, serum, urine proteomics and metaproteomics were conducted for healthy control (HC), CD and CDPS subjects. Wild-type (WT) C57BL/6J, Hgfac knockout and Krt7 knockout mice (male, 8-10 weeks old) were studied using the Dextran Sulfate Sodium (DSS) induced colitis model and imiquimod induced psoriasis model.
findingsTen patients with CDPS were enrolled. All patients had infliximab (IFX) exposure history but the IFX response rates were lower. The disease site (L3) and perianal lesions of the CDPS group showed statistically significant differences compared with those in the CD group. Moreover, blood inflammatory indicators and triglyceride levels were higher in the CDPS group. Meanwhile, significant differences were observed in the age of onset, PS type, and PS activity score between the CDPS group and the idiopathic PS group. Therapeutic response results showed that all the patients experienced improvement of their PS whilst some of their intestinal lesions remained active after the treatment with ustekinumab (UST). Additionally, Intestinal mucosa proteomic results showed that CDPS group exhibited higher activation of immune-related pathways, increased keratin formation and impaired intestinal mucosal mitochondrial function leading to reduced activity of metabolism-related pathways. Serum and urine proteomics revealed that the significant downregulation of hepatocyte growth factor activator (HGFAC) in patients with CDPS impedes lipid metabolism. Metaproteomic analysis showed that the CDPS group had reduced abundance of lipid metabolism-associated microbes, leading to increased lipid deposition in the intestinal mucosa and consequently, an enhanced inflammatory response. And in animal experiments, HGFAC knockout mice developed markedly more severe colitis and skin inflammation, whereas KRT7 knockout mice and those Megasphaera micronuciformis treated mice exhibited attenuated disease phenotypes.
interpretationPatients with CD who have extensive and perianal lesions are more likely to develop PS. Furthermore, patients with CDPS suffer from more severe disease progression, poorer prognosis and lower response rate to biological agents. Aberrant activation of immune signalling in the intestinal mucosa, increased expression of keratins and impaired mitochondrial metabolic function are potential reasons for the more severe intestinal inflammation in patients with CDPS. Downregulation of circulating HGFAC and reduction of microbes associated with lipid metabolism elevate blood triglyceride levels, and triglycerides lead to significant activation of immune cells in the skin, which is accompanied by an increase in circulating immunoglobulins, which may represent a key mechanism for the development of PS in patients with CD. Our study has elucidated the potential pathogenesis of CDPS, and the combination of clinical and proteomic analysis may provide valuable insights for reference into the management and therapeutic targets of this type of comorbidity.
fundingThis work was supported by the National Natural Science Funds of China (82370529, 82303391), the Guangdong Basic and Applied Basic Research Fund (2022A1515111193), the Guangzhou Science and Technology Plan Project (2023A04J0581), the Featured Clinical Technique of Guangzhou (2023C-TS34), and the Science and Technology Projects in Guangzhou (202201020142 and 2024B03J0466).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.